Hormone and Metabolic Research最新文献

Elevated Serum Creatine Kinase During the Treatment of Patients with Graves' Disease with Antithyroid Drugs: New Insights into an Old Issue. 抗甲状腺药物治疗Graves病患者血清肌酸激酶升高：一个老问题的新认识

IF 1.8 4区医学

Hormone and Metabolic Research Pub Date : 2025-07-28 DOI: 10.1055/a-2652-9079

Yuji Nagayama, Seigo Tachibana, Takashi Fukuda, Kento Katsuyama, Daisuke Tatsuyama, Yusuke Mori, Hisakazu Shindo, Hiroshi Takahashi, Shinya Sato, Hiroyuki Yamashita

{"title":"Elevated Serum Creatine Kinase During the Treatment of Patients with Graves' Disease with Antithyroid Drugs: New Insights into an Old Issue.","authors":"Yuji Nagayama, Seigo Tachibana, Takashi Fukuda, Kento Katsuyama, Daisuke Tatsuyama, Yusuke Mori, Hisakazu Shindo, Hiroshi Takahashi, Shinya Sato, Hiroyuki Yamashita","doi":"10.1055/a-2652-9079","DOIUrl":"https://doi.org/10.1055/a-2652-9079","url":null,"abstract":"Serum creatine kinase (CK) elevation can occur in some patients with Graves' disease treated with antithyroid drugs (ATDs). This study retrospectively investigated clinical characteristics and biochemical data of patients with Graves' disease who experienced serum CK elevation during ATD treatment. CK elevation was observed in 29.6% (37/125) of patients, with 11.2% (14/125) being symptomatic. This incidence is higher than previously reported (13.5%). There were no differences in pre-treatment characteristics between patients with and without CK elevation. The intervals between the initiation of ATD treatment or normalization of thyroid function and the onset of CK elevation were 11.3±8.0 and 5.8±6.6 weeks, respectively, and peak serum CK levels averaged 441.9±394.0 IU/l. Markedly elevated serum CK were accompanied by increased serum myoglobin levels. Serum CK elevation occurred either continuously or intermittently, or as a single episode during the course of treatment. Thyroid function at the time of CK elevation varied from hyperthyroid to normal to hypothyroid. In conclusion, serum CK elevation in patients with Graves' disease treated with ATDs is not uncommon, with symptomatic cases accounting for approximately 10%, and the frequency increasing to around 30% when asymptomatic cases are included. The characteristics observed in our patients suggest the involvement of alternative, as yet unknown mechanisms beyond the relative hypothyroidism theory and the ATD side-effect theory in the development of CK elevation during ATD treatment in patients with Graves' disease.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144730083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CGM-Based Real-World Data on the Transition from Glargine U100 to U300 in Children and Adolescents with Type 1 Diabetes. 基于cgm的儿童和青少年1型糖尿病患者从甘精胰岛素U100到U300转换的真实世界数据

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-07-15 DOI: 10.1055/a-2634-8614

Gürkan Tarçın

{"title":"CGM-Based Real-World Data on the Transition from Glargine U100 to U300 in Children and Adolescents with Type 1 Diabetes.","authors":"Gürkan Tarçın","doi":"10.1055/a-2634-8614","DOIUrl":"10.1055/a-2634-8614","url":null,"abstract":"This study aimed to compare continuous glucose monitoring (CGM) parameters in children and adolescents with Type 1 diabetes (T1D) who transitioned from glargine U100 to glargine U300 to evaluate efficacy and safety. A total of 52 participants aged 6-18 years using CGM were analyzed before and after transitioning from glargine U100 to glargine U300. For each individual, a 2-week CGM data collection was conducted after optimizing the glargine U100 dose. Participants then switched to glargine U300 at the same dose, with doses adjusted based on CGM graphs every three days. One week after the final dose adjustment, a second 2-week CGM period was recorded. Additionally, nighttime (00:00-08:00 h) data were analyzed, with glucose fluctuations measured by coefficient of variation (CV) and root mean squared error (RMSE). All parameters were compared between glargine U100 and U300. No significant differences were observed in glucose management indicator (GMI) or time in range (TIR) between glargine U100 and U300. However, glargine U300 was associated with significantly reduced hypoglycemia frequency and duration across 24-hour and nocturnal periods. Lower CV and RMSE values during nighttime further indicated reduced glycemic variability with glargine U300. An average 10% increase in basal insulin dose was required following the transition. The study provides real-world, CGM-based evidence suggesting that glargine U300 offers a safer, more stable option for managing T1D in children, particularly in reducing hypoglycemia. These findings highlight glargine U300's potential advantages in glycemic stability, supporting its use in pediatric diabetes care.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Growth Hormone-Releasing Hormone and the Hypothalamic-Pituitary-Somatotropic Axis in Aging: Potential Therapeutic Applications and Risks. 生长激素释放激素和下丘脑-垂体-体促轴在衰老中的作用：潜在的治疗应用和风险。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-07-11 DOI: 10.1055/a-2641-1207

Ioannis Oikonomakos, Richard Siow, Stefan R Bornstein, Charlotte Steenblock

{"title":"The Role of Growth Hormone-Releasing Hormone and the Hypothalamic-Pituitary-Somatotropic Axis in Aging: Potential Therapeutic Applications and Risks.","authors":"Ioannis Oikonomakos, Richard Siow, Stefan R Bornstein, Charlotte Steenblock","doi":"10.1055/a-2641-1207","DOIUrl":"https://doi.org/10.1055/a-2641-1207","url":null,"abstract":"Aging is marked by a gradual decline in multiple physiological functions, increasing the risk of age-related disorders. Multiple factors have been identified as contributors to aging, many of which are regulated by the hypothalamus. Growth hormone-releasing hormone (GHRH) produced in the hypothalamus is a key regulator of growth hormone (GH) secretion. With aging, both GHRH and GH levels decline, leading to muscle loss, increased fat accumulation, metabolic dysregulation, and cognitive impairments. GH replacement therapy has been explored as a potential intervention to counteract these effects; however, its long-term use is associated with significant risks, including metabolic disturbances, cardiovascular complications, and potential cancer promotion. In contrast, studies suggest that GHRH-based therapies can improve body composition, muscle strength, cognitive function, and cardiovascular health while avoiding the risks linked to direct GH administration. Additionally, preclinical findings indicate that GHRH agonists may offer cardioprotective and immunomodulatory benefits. In this review, we summarize current knowledge on the roles of GHRH and GH in aging, highlight the limitations of GH-based therapies, and discuss the potential of GHRH-based approaches in mitigating age-related decline and improving health span.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144617391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic and Hormonal Profile of Insulin-Like Peptide 5 (INSL5) in Polycystic Ovary Syndrome: A Prospective Analysis. 多囊卵巢综合征中胰岛素样肽5 （INSL5）的代谢和激素特征：一项前瞻性分析

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-07-01 DOI: 10.1055/a-2636-9491

Deniz Cengiz, Esra Nur Ademoğlu Dilekçi, Ömür Albayrak, Özgür Mehmet Yis

{"title":"Metabolic and Hormonal Profile of Insulin-Like Peptide 5 (INSL5) in Polycystic Ovary Syndrome: A Prospective Analysis.","authors":"Deniz Cengiz, Esra Nur Ademoğlu Dilekçi, Ömür Albayrak, Özgür Mehmet Yis","doi":"10.1055/a-2636-9491","DOIUrl":"https://doi.org/10.1055/a-2636-9491","url":null,"abstract":"Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder with diverse metabolic and hormonal manifestations. Insulin-like peptide 5 (INSL5), a gut-derived hormone of the relaxin/insulin family, is expressed in the central nervous system, colonic and reproductive tissues, but its clinical significance in PCOS remains unclear. This study aimed to evaluate circulating INSL5 levels in PCOS and explore their associations with key hormonal and metabolic parameters. In this prospective cross-sectional study, 45 women with newly diagnosed PCOS and 35 age-matched healthy controls (18-35 years) were evaluated. Clinical characteristics, hormonal profiles, and metabolic markers - including serum anti-Müllerian hormone (AMH) and INSL5 - were assessed. INSL5 levels were measured using enzyme-linked immunosorbent assay (ELISA). Median serum INSL5 levels did not differ significantly between PCOS and control groups (12.5 vs. 15.5 ng/ml; p=0.103). However, within the PCOS group, INSL5 was inversely correlated with body mass index, insulin, HOMA-IR, total and LDL cholesterol, triglycerides, fat mass, and free androgen index, and positively correlated with sex hormone-binding globulin (p<0.05 for all). AMH was significantly higher in the PCOS group and demonstrated a diagnostic cut-off of 5.04 ng/ml (AUC: 0.808; sensitivity: 75.6%; specificity: 74.3%). Although INSL5 did not show diagnostic utility for PCOS, its consistent associations with insulin resistance, androgenic activity, and lipid metabolism suggest a potential role in metabolic regulation. These findings support its relevance as a candidate marker for metabolic phenotyping and warrant further investigation into its physiological role within the PCOS spectrum.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Associations of Obesity, Vitamin D, Adjusted Total Calcium, and Parathyroid Hormone in US from NHANES. 美国肥胖、维生素D、调整总钙和甲状旁腺激素的相关性

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-06-27 DOI: 10.1055/a-2638-1810

Ethan Frank, Eric Adjei Boakye, Brendan C Stack

{"title":"Associations of Obesity, Vitamin D, Adjusted Total Calcium, and Parathyroid Hormone in US from NHANES.","authors":"Ethan Frank, Eric Adjei Boakye, Brendan C Stack","doi":"10.1055/a-2638-1810","DOIUrl":"https://doi.org/10.1055/a-2638-1810","url":null,"abstract":"Evidence for obesity and vitamin D deficiency as components of a data phenotype for primary hyperparathyroidism (pHPT) is critical to understanding primary hyperparathyroidism. This study examined the association between vitamin D, body mass index (BMI), albumin total calcium, parathyroid hormone (PTH) and data from National Health and Nutrition Examination Survey (NHANES). Associations of 25-hydroxyvitamin D, albumin adjusted calcium, and BMI with elevated PTH were evaluated, with elevated PTH being defined as>9.02 pmol/l. Outcomes were PTH (pmol/l), 25-hydroxyvitamin D (nmol/l), albumin adjusted calcium (mmol/l), and BMI. A weighted multivariable logistic regression model estimated the associations. A total of 9740 survey respondents were included in the study, 3.5% had elevated PTH. Mean vitamin D level was 57.7 (SD=22.6) nmol/l and BMI was 28.6 (SD=6.5) kg/m2. A one unit increase in BMI was associated with higher odds of elevated PTH [adjusted odds ratio (aOR)=1.04; 95% confidence interval (CI): 1.02, 1.06] whereas a one unit increase in vitamin D (aOR=0.97; 95% CI: 0.96, 0.98) or calcium (aOR=0.51; 95% CI: 0.29, 0.89) had decreased odds of elevated PTH. Higher BMI and lower levels of 25-hydroxyvitamin D are components of the primary hyperparathyroidism data phenotype. A refined data phenotype may improve detection/management of pHPT.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Asymmetric Dimethylarginine: A Never-Aging Story. 更正：不对称二甲基精氨酸：一个永不老化的故事。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-06-10 DOI: 10.1055/a-2626-3601

Natalia Jarzebska, Stefan R Bornstein, Sergey Tselmin, Ulrich Julius, Barbara Cellini, Richard Siow, Mike Martin, Rajeshwar P Mookerjee, Arduino A Mangoni, Norbert Weiss, Roman N Rodionov

引用次数: 0

Oxidative Stress Parameters are Differentially Regulated in Visceral and Subcutaneous Adipose Tissue by Western Diet and Intermittent Fasting. 西方饮食和间歇性禁食对内脏和皮下脂肪组织氧化应激参数的调节存在差异。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-06-01 Epub Date: 2025-07-07 DOI: 10.1055/a-2634-0201

Niedson Correia de Lima Junior, Thayara Fernandes-Batista, Letícia Ferreira-Serra, Ana Luísa Paes-Dias, Leonardo Matta-Pereira, Fabio Hecht Castro Medeiros, Carmen Cabanelas Pazos-Moura, Rodrigo Soares Fortunato, Denise Pires Carvalho, Glaecir Roseni Mundstock Dias, Andrea Cf Ferreira

{"title":"Oxidative Stress Parameters are Differentially Regulated in Visceral and Subcutaneous Adipose Tissue by Western Diet and Intermittent Fasting.","authors":"Niedson Correia de Lima Junior, Thayara Fernandes-Batista, Letícia Ferreira-Serra, Ana Luísa Paes-Dias, Leonardo Matta-Pereira, Fabio Hecht Castro Medeiros, Carmen Cabanelas Pazos-Moura, Rodrigo Soares Fortunato, Denise Pires Carvalho, Glaecir Roseni Mundstock Dias, Andrea Cf Ferreira","doi":"10.1055/a-2634-0201","DOIUrl":"https://doi.org/10.1055/a-2634-0201","url":null,"abstract":"The consumption of Western diet, characterized by high sugar and saturated fat content, often leads to weight gain and promotes oxidative stress. Intermittent fasting has emerged as a potential strategy to combat obesity, but its effects on redox homeostasis in white adipose tissue compartments remain unclear. In this study, male Wistar rats were fed a regular or Western diet ad libitum or subjected to an intermittent fasting regimen, consisting of 1-day fasting followed by 2 days of free access to food, over 12 weeks. Elevated superoxide anion levels were observed in visceral adipose tissue of both Western diet-fed groups, independent of the regimen, along with decreased nicotinamide adenine dinucleotide phosphate oxidase activity and increased catalase activity, suggesting an adaptive response to mitigate oxidative stress. In the same tissue, superoxide dismutase activity was reduced, indicating that impaired dismutation might be responsible for the increment of superoxide levels. Intermittent fasting increased the expression of catalase and superoxide dismutase, but this effect was not observed at activity levels. Thus, our data suggest that Western diet impaired the beneficial effect of intermittent fasting on antioxidant activity in visceral adipose tissue. Interleukin-6 mRNA levels were increased by Western diet ad libitum in visceral adipose tissue, but this effect was impaired by intermittent fasting, suggesting an anti-inflammatory effect of intermittent fasting. Redox balance in subcutaneous adipose tissue remained unchanged. In conclusion, intermittent fasting alone did not prevent the oxidative stress caused by Western diet in visceral adipose tissue, despite having an anti-inflammatory action.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":"57 6","pages":"396-404"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship Between the Triglyceride-Glucose Index and Chronic Kidney Disease: A Meta-Analysis of Cohort Studies. 甘油三酯-葡萄糖指数与慢性肾脏疾病的关系：队列研究的荟萃分析

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-06-01 Epub Date: 2025-07-07 DOI: 10.1055/a-2634-0157

Miaohong Wang, Wenxuan Xu, Huan Shi

{"title":"Relationship Between the Triglyceride-Glucose Index and Chronic Kidney Disease: A Meta-Analysis of Cohort Studies.","authors":"Miaohong Wang, Wenxuan Xu, Huan Shi","doi":"10.1055/a-2634-0157","DOIUrl":"10.1055/a-2634-0157","url":null,"abstract":"Previous studies investigating the relationship between the triglyceride-glucose (TyG) index, a novel marker of insulin resistance (IR), and the risk of chronic kidney disease (CKD) in the general population have reported conflicting findings. Therefore, we conducted this meta-analysis to systematically evaluate the association between the TyG index and CKD risk. Cohort studies estimating the multivariate-adjusted association between TyG index and CKD were attained by thoroughly retrieving five databases including PubMed, Cochrane Library, Embase, Scopus, and Web of Science. A random-effects model was used to analyze the data. Eleven cohort studies comprising 86 038 participants without CKD at baseline were included. Results showed that higher TyG index were independently associated with a higher risk of CKD for highest versus lowest TyG index category [adjusted RR: 1.52, 95% CI: 1.38-1.67, I2=0%, p<0.001]. The results with the TyG index analyzed continuously showed consistent (adjusted RR per each unit increase of TyG index: 1.29, 95% CI 1.22-1.36, I2=0%, p<0.001). Findings of sensitivity analysis, which ruled out one dataset at a time, was similar (adjusted RR for categorical variables: 1.48-1.60, all p<0.001; adjusted R for continuous variables: 1.28-1.38, all p<0.001). Subgroup analyses suggested study features including ethnicity, sex, mean age, source of subjects, and the quality scores of studies had no significant effect on the association (all p>0.05). To summarize, a higher TyG index may be independently associated with a higher incidence of CKD in people without CKD at baseline.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":"57 6","pages":"385-395"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expression Profiles of Glucocorticoid Receptor α- and β-Isoforms in Diverse Physiological and Pathological Conditions. 糖皮质激素受体α-和β-亚型在不同生理和病理条件下的表达谱。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-06-01 Epub Date: 2025-05-22 DOI: 10.1055/a-2619-5035

Xiang Chen, Hongyu He

{"title":"Expression Profiles of Glucocorticoid Receptor α- and β-Isoforms in Diverse Physiological and Pathological Conditions.","authors":"Xiang Chen, Hongyu He","doi":"10.1055/a-2619-5035","DOIUrl":"10.1055/a-2619-5035","url":null,"abstract":"Through alternative splicing, two isoforms of the glucocorticoid receptor (GR) gene are generated, termed GRα and GRβ. GRα is predominantly expressed and shows steroid binding activity, whereas GRβ is thought to be inactive as a result of its truncated ligand-binding domain. GRβ may only act as a dominant negative inhibitor when co-expressed with GRα. GRβ specifically binds RU486 and also exhibits intrinsic transcriptional activities to directly regulate the expression of a large number of genes via both GRα-dependent and GRα-independent mechanisms. Hypercortisolemia and hypocortisolemia show different effects on the expression profiles of GR isoforms. Inflammatory cytokines induce GRβ expression and lead to an increased GRβ/GRα ratio, which may be related to glucocorticoid resistance during inflammatory diseases. Because GRβ inhibits the activity of GRα, it has the potential to ameliorate glucocorticoid-induced abnormal metabolism, muscle loss or be used to treat tumors. While elevated GRβ expression has been found in some inflammatory diseases and may be relevant to glucocorticoid unresponsiveness, whether GRβ modulates glucocorticoid sensitivity in vivo is under debate because of its extremely low expression levels under physiological situations.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":"359-365"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus and its Impact on C-Peptide Levels. 西马鲁肽注射液治疗2型糖尿病的疗效及对c肽水平的影响。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-06-01 Epub Date: 2025-06-05 DOI: 10.1055/a-2618-7509

Shuying Xie, Lan Ye, Anyuan Yang, Xiaoyan Li, Ying Yin

{"title":"Efficacy of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus and its Impact on C-Peptide Levels.","authors":"Shuying Xie, Lan Ye, Anyuan Yang, Xiaoyan Li, Ying Yin","doi":"10.1055/a-2618-7509","DOIUrl":"10.1055/a-2618-7509","url":null,"abstract":"Type 2 Diabetes Mellitus (T2DM) remains a significant global health challenge, necessitating more effective therapeutic strategies. This study was to observe the impact of semaglutide on the C-Peptide levels and glycemic variability. This retrospective evaluation was conducted from January 2020 to January 2023 at our hospital, involving 172 patients diagnosed with T2DM. Patients were stratified into two groups: the observation group (86 patients) received semaglutide injections plus metformin, and the control group (86 patients) received only metformin. Treatment efficacy was assessed using changes in HbA1c, fasting blood glucose (FBG), 2-hour postprandial blood glucose (2 h BG), and C-Peptide levels. Additional evaluations included changes in glycemic variability indicators such as standard deviation of blood glucose (SDBG), mean of daily differences (MODD), and mean amplitude of glycemic excursions (MAGE). The observation group showed significantly greater improvements in glycemic control and C-Peptide levels compared to the control group. Specifically, the observation group achieved a significant reduction in HbA1c from 70 mmol/mol to 53 mmol/mol, FBG from 10.91 mmol/l to 6.12 mmol/l, and increased C-Peptide levels in both fasting and postprandial states. Improvements in glycemic variability were also more pronounced in the observation group. There was no significant difference in the incidence of adverse events between the two groups. Semaglutide combined with metformin significantly enhances the efficacy of treatment in T2DM patients, with marked improvements in C-Peptide levels, glycemic control, and reduction in glycemic variability. This combination therapy not only offers superior glucose management but also appears to bolster pancreatic function.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":"378-384"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0